These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31506218)

  • 21. Compatibility of doripenem with other drugs during simulated Y-site administration.
    Brammer MK; Chan P; Heatherly K; Trusley C; Kupiec TC; Trissel LA; Psathas PA; Gilmor T; Schaufelberger D
    Am J Health Syst Pharm; 2008 Jul; 65(13):1261-5. PubMed ID: 18574017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
    Lee TM; Villareal CL; Meyer LM
    Hosp Pharm; 2021 Aug; 56(4):282-286. PubMed ID: 34381262
    [No Abstract]   [Full Text] [Related]  

  • 23. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.
    Berti AD; Hutson PR; Schulz LT; Webb AP; Rose WE
    Am J Health Syst Pharm; 2015 Mar; 72(5):390-5. PubMed ID: 25694414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
    Trissel LA; Williams KY; Gilbert DL
    J Am Pharm Assoc (Wash); 2000; 40(4):515-9. PubMed ID: 10932461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
    Katip W
    Am J Health Syst Pharm; 2017 Jul; 74(14):1099-1102. PubMed ID: 28687555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
    Wilder AG; Foushee JA; Fox LM; Navalle J; Wright AM; Greer MA
    Int J Pharm Compd; 2020; 24(3):238-241. PubMed ID: 32401743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery.
    Condie CK; Tyler LS; Barker B; Canann DM
    Am J Health Syst Pharm; 2008 Mar; 65(5):454-7. PubMed ID: 18281738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eravacycline, a newly approved fluorocycline.
    Lee YR; Burton CE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compatibility of micafungin injection with other drugs during simulated y-site co-administration.
    Trusley C; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2006; 10(3):230-3. PubMed ID: 23974236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
    Foushee JA; Meredith P; Fox LM; Grace E
    Int J Pharm Compd; 2016; 20(4):328-332. PubMed ID: 28333677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
    Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
    Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC; Trusley C; Ben M; Trissel LA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1735-59. PubMed ID: 18769000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eravacycline: A Review in Complicated Intra-Abdominal Infections.
    Scott LJ
    Drugs; 2019 Feb; 79(3):315-324. PubMed ID: 30783960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
    Najari Z; Rusho WJ
    Am J Health Syst Pharm; 1997 Jan; 54(2):181-4. PubMed ID: 9117807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
    Ross EL; Salinas A; Petty K; Her C; Carpenter JF
    Am J Health Syst Pharm; 2020 Nov; 77(23):1980-1985. PubMed ID: 32974650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eravacycline for the treatment of patients with bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Apr; 54(4):245-254. PubMed ID: 29869646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
    Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
    Solomkin JS; Sway A; Lawrence K; Olesky M; Izmailyan S; Tsai L
    Future Microbiol; 2019 Oct; 14():1293-1308. PubMed ID: 31570004
    [No Abstract]   [Full Text] [Related]  

  • 40. Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications.
    Ghazi IM; El Nekidy WS; Sood A; Dulku A; Patel R; Patel K; Li P
    Clin Ther; 2020 Mar; 42(3):475-485. PubMed ID: 32139175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.